Przejdź do zawartości
Merck

Discovery of 1-arylcarbonyl-6,7-dimethoxyisoquinoline derivatives as glutamine fructose-6-phosphate amidotransferase (GFAT) inhibitors.

Bioorganic & medicinal chemistry letters (2011-10-01)
Yimin Qian, Mushtaq Ahmad, Shaoqing Chen, Paul Gillespie, Nam Le, Frank Mennona, Steven Mischke, Sung-Sau So, Hong Wang, Charles Burghardt, Shahid Tannu, Karin Conde-Knape, Jarema Kochan, David Bolin
ABSTRAKT

Through high throughput screening and subsequent hit identification and optimization, we synthesized a series of 1-arylcarbonyl-6,7-dimethoxyisoquinoline derivatives as the first reported potent and reversible GFAT inhibitors. SAR studies of this class of compounds indicated significant impact on GFAT inhibition potency by substitutions on the A-ring and C-ring. The ketone group was found to be necessary for high potency. Compound 28 (RO0509347) demonstrated potent GFAT inhibition (IC(50)=1μM) with a desirable pharmacokinetic profile in rats, and showed significant efficacy in reducing the glucose excursion in an OGTT test in ob/ob mice.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
D-Fructose 6-phosphate disodium salt hydrate, ≥98%, amorphous powder
Sigma-Aldrich
D-Fructose 6-phosphate dipotassium salt, ≥97% (enzymatic), amorphous powder